The 800-Lb. Gorilla: Drug Costs Loom Large In Medicare Oncology Care Model
Executive Summary
Drug costs make up 60% of the total cost of cancer care, participants in the Medicare Oncology Care Model have found. But efforts to manage spending under the demonstration have so far focused instead on areas that represent a smaller portion of overall costs, such as hospitalizations.
You may also be interested in...
CMS Innovation Center Exploring ‘Array’ Of Cost-Lowering Medicare Payment Models
CMMI payment demonstrations are viewed as way of skirting statutory obstacles to experimenting with new approaches to reimbursement and could lead to significant drug pricing reforms if legislative efforts fail. However, HHS is not signaling an intent to pursue transformational new models at this point.
Medicare Drug Pricing Demonstration Agenda May Be Reshaped By Fowler As CMMI Head
Elizabeth Fowler brings combination of Capitol Hill, White House and pharma industry experience to the role of director of the Center for Medicare and Medicaid Innovation.
US Medicare Oncology Demo Should Test Value-Based Drug Pricing – Providers
Community Oncology Alliance proposes updates to the Oncology Care Model demonstration project, including a sharper focus on lowering prescription drug costs.